{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-119654","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.953267+00:00","generated_at":"2026-05-16T13:45:26.130318+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Fennec announces City of Hope IST testing PEDMARK in adult testicular germ cell tumors","bullets":["Phase I study (NCT07218913) evaluating PEDMARK to prevent cisplatin-induced ototoxicity in adults with stage II-III metastatic testicular germ cell tumors.","Principal investigator: Alexander Chehrazi-Raffle, M.D., at City of Hope, Duarte, CA.","PEDMARK is currently approved for pediatric patients with localized solid tumors; this expands investigation into adult metastatic setting.","Multiple other investigator-initiated studies submitted or in advanced contracting stages.","Fennec's CMO cites need for hearing protection in cisplatin-treated survivors; study aims to change standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-119654","json":"https://secwatch.observer/filing/0001104659-25-119654.json","markdown":"https://secwatch.observer/filing/0001104659-25-119654.md","text":"https://secwatch.observer/filing/0001104659-25-119654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465925119654/0001104659-25-119654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465925119654/fencf-20251209x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:45:26.130318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}